C2 Human shRNA Plasmid Kit (Locus ID 717)

Specifications

Product Data
Locus ID	717
Synonyms	ARMD14; CO2
Vector	pGFP-C-shLenti
E. coli Selection	Chloramphenicol (34 ug/ml)
Mammalian Cell Selection	Puromycin
Format	Lentiviral plasmids
Kit Components	C2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 717). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq	BC029781, NM_000063, NM_001145903, NM_001178063, NM_001282457, NM_001282458, NM_001282459, NR_073063, NM_000063.1, NM_000063.2, NM_000063.3, NM_000063.4, NM_000063.5, NM_001145903.1, NM_001145903.2, NM_001178063.1, NM_001178063.2, NM_001282459.1, NM_001282457.1, NM_001282458.1, BC029781.1, BC043484, BC043484.1, NM_001282457.2, NM_001282459.2, NM_000063.6, NM_001145903.3, NM_001282458.2
UniProt ID	P06681
Summary	Component C2 is a serum glycoprotein that functions as part of the classical pathway of the complement system. Activated C1 cleaves C2 into C2a and C2b. The serine proteinase C2a then combines with complement factor 4b to create the C3 or C5 convertase. Deficiency of C2 has been reported to associated with certain autoimmune diseases and SNPs in this gene have been associated with altered susceptibility to age-related macular degeneration. This gene localizes within the class III region of the MHC on the short arm of chromosome 6. Alternative splicing results in multiple transcript variants encoding distinct isoforms. Additional transcript variants have been described in publications but their full-length sequence has not been determined.[provided by RefSeq, Mar 2009]
shRNA Design	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact tech@biotrend.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Performance Guaranteed	OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at tech@biotrend.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).